News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Article

Pharmaceutical Executive

January 6, 2020

Six Personalized and Digital Health Trends

Author(s):

Mark Lambrecht, PhD

A list of six trends for 2020 in the age of digital and personalized health.

  • Augmented clinical trials bring many advantages to consume digital patient-centric information and optimize clinical development. Virtual, pragmatic, and hybrid trial designs will improve patient enrollment, compliance, and experience. They will also lead to improved trial outcomes as patient adherence, clinical biomarkers, and other areas of clinical benefit are more easily measured and analyzed during development. Additionally, decisions to protect patients against possible adverse events or risks of supply shortage can be addressed in real time. Artificial Intelligence (AI) and machine learning, supported by the Internet of Medical Things (IoMT), will serve as the analytics engine to enable this innovation in trial design by keeping patients and their data connected with researchers. 
     

  • Pharmaceutical manufacturing is becoming increasingly digitalized and processes are changing to benefit from robotic process automation, digital twin simulation, and digital operator assistance (e.g., augmented reality approaches, use of image analytics). 
     

  • In health care, social determinants of health are being applied to detect populations at risk of escalating health costs due to chronic diseases, demographics or behavioral patterns. An example is the use of income data or access to education; data points that can affect how people take care of their health. Secure data zones and data privacy guardians will need to be established to respect personal data privacy regulations (such as the EU’s GDPR) and to avoid unethical uses of data.
     

  • New primary care delivery models-“new digital front doors of health care”-are being established to help drive better patient outcomes, lower costs, and increase the ability of health care providers, payers, and governments to significantly impact health budgets. These models encompass extending primary care through virtual clinics, offering telemedicine services and virtual consults, and pharmacy chains establishing basic clinical care to facilitate patient access. These digitalized services, combined with analytics, machine learning, and AI, have the potential to transform the patient journey from the inside out.
     

  • We have just seen the start of a new revolution in medicine with in-vivo gene therapies combating the effects of mutations in somatic cells directly inside the body. These therapies (e.g., CAR-T, CRISPR-CAS9, RNAi, healthy gene delivery mechanisms) constitute a huge paradigm shift and bring a level of precision to the clinic not yet seen in clinical reality, although promised by researchers for a long time. However, the therapy (curing disease by changing faulty gene expression or translation, and their development and manufacturing processes) is very expensive. New cost models will need to be established for payers to decide on reimbursement and weigh the value against lifetime chronic disease states and the accompanying treatment regimens.
     

  • Artificial Intelligence is becoming available to everyone and can be used everywhere in health care and life sciences processes where information environments are kind to AI and dense, high quality, and integrated data are available (e.g., CT scans, EHR, clinical trial data, financial data). More attention will need to be given to semantically integrate data, as well as transparency and interoperability, for organizations to reap the benefits of these transformative technologies.

 

Mark Lambrecht, PhD, director of the SAS Global Health and Life Sciences Practice

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 3rd 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Cell and Gene Therapy Check-in 2024
August 3rd 2025

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Earned Media and PBMs: Proactive Pathways for Image Boost
August 3rd 2025

Earned Media and PBMs: Proactive Pathways for Image Boost

Michael Christel
Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through transparency, storytelling, and leveraging data to improve patient care.
Industry Outlook 2022
August 3rd 2025

Industry Outlook 2022

Elaine Quilici Miranda Schmalfuhs
Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition
August 3rd 2025

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition

Don Tracy, Associate Editor
Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in its strategic plans amid recent market challenges.
Earned Media and ASCO: Provide Context Beyond the Data
August 3rd 2025

Earned Media and ASCO: Provide Context Beyond the Data

Michael Christel
The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.
Related Content
Advertisement
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 3rd 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Cell and Gene Therapy Check-in 2024
August 3rd 2025

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Earned Media and PBMs: Proactive Pathways for Image Boost
August 3rd 2025

Earned Media and PBMs: Proactive Pathways for Image Boost

Michael Christel
Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through transparency, storytelling, and leveraging data to improve patient care.
Industry Outlook 2022
August 3rd 2025

Industry Outlook 2022

Elaine Quilici Miranda Schmalfuhs
Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition
August 3rd 2025

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition

Don Tracy, Associate Editor
Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in its strategic plans amid recent market challenges.
Earned Media and ASCO: Provide Context Beyond the Data
August 3rd 2025

Earned Media and ASCO: Provide Context Beyond the Data

Michael Christel
The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.